Evidence map›Paper›PMID 37679245›Full record

ReviewChinese journal of traumatology = Zhonghua chuang shang za zhi2024

Targeting the adenosine A

Yan Zhao, Yuan-Guo Zhou, Jiang-Fan Chen

Abstract readReview
In one paragraph

Review in Chinese journal of traumatology = Zhonghua chuang shang za zhi, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. A Sesquiterpenoid fromInternational journal of molecular sciences · 2026
    Article
  2. Review
  3. Review
  4. Neurotransmitter Systems in Alzheimer's Disease.Current issues in molecular biology · 2026
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Caffeine in Aging Brains: Cognitive Enhancement, Neurodegeneration, and Emerging Concerns About Addiction.International journal of environmental research and public health · 2025
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yan ZhaoDepartment of Army Occupational Disease, State Key Laboratory of Trauma, Burns and Combined Injury, Research Institute of Surgery, Daping Hospital, Army Medical University, Chongqing, 400042, China.
Yuan-Guo ZhouDepartment of Army Occupational Disease, State Key Laboratory of Trauma, Burns and Combined Injury, Research Institute of Surgery, Daping Hospital, Army Medical University, Chongqing, 400042, China.
Jiang-Fan ChenThe Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China; Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Wenzhou, 325035, Zhejiang Province, China. Electronic address: chenjf555@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adenosine exerts its dual functions of homeostasis and neuromodulation in the brain by acting at mainly 2 G-protein coupled receptors, called A

Indexed as

Adenosine A2 Receptor AntagonistsBrain Injuries, TraumaticParkinson DiseaseReceptor, Adenosine A2AAnimalsCognitionCognitive DysfunctionHumansNeuroprotectionNeuroprotective AgentsPurinesAdenosine A2 Receptor AntagonistsistradefyllineNeuroprotective AgentsPurinesReceptor, Adenosine A2AAdenosine A(2) receptor antagonistsBrain injuries, traumaticParkinson's diseaseReceptor, Adenosine A(2A)

Identifiers

PMID37679245
PMCPMC11138351

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.